What one share of Annovis Bio holds
We are a late-stage clinical drug platform company addressing neurodegeneration, such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). We are developing our lead product candidate, buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases.
Annovis Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$1.79 |
| Cash and investments | $0.44 |
| Book value | −$0.10 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$3.51 | — | — | — | −$30.35 |
| 2020 | $0.00 | −$0.87 | — | — | — | $1.09 |
| 2021 | $0.00 | −$1.90 | — | — | — | $5.49 |
| 2022 | $0.00 | −$3.10 | — | — | — | $3.47 |
| 2023 | $0.00 | −$6.23 | — | — | — | −$0.74 |
| 2024 | $0.00 | −$2.31 | — | — | — | $0.66 |
| 2025 | $0.00 | −$1.40 | — | — | — | $0.62 |
Common questions about Annovis Bio
How much does one share of Annovis Bio earn?
Over the last 12 months, Annovis Bio lost $1.79 for each share.
Does Annovis Bio pay a dividend?
Annovis Bio didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Annovis Bio’s book value per share?
Annovis Bio’s book value is negative (−$0.10 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Annovis Bio have?
Each share of Annovis Bio has $0.44 of cash and investments, as of June 30, 2026.
Has Annovis Bio bought back shares?
Annovis Bio’s share count rose about 7172% from 2019 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.